• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Neogen's Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification

    4/23/26 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NEOG alert in real time by email

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced that its Molecular Detection Assay - Listeria Right Now™ rapid environmental monitoring test has received AOAC® Performance Tested Methods℠ (PTM) certification (No. 042604), validating the test's performance for the enrichment-free detection of viable and non-viable Listeria species on stainless steel surfaces. The technology allows technicians to perform the assay without first enriching the sample by growing the bacteria in culture media. Combined with the ease-of-use and speed advantages associated with Neogen's Molecular Detection System ™, this makes Neogen's test one of the fastest molecular tests available for Listeria species testing.

    The AOAC PTM program is an internationally recognized third-party validation that confirms a method performs as claimed and meets rigorous performance standards. Certification of Listeria Right Now demonstrates Neogen's commitment to delivering scientifically validated, regulator-recognized solutions that support food safety programs worldwide.

    Listeria Right Now is designed to deliver clear, actionable results from samples, without an enrichment step, in about two hours. This allows food manufacturers to quickly identify potential contamination risks and strengthen environmental monitoring workflows. The test integrates seamlessly into existing food safety programs and supports proactive decision-making across a wide range of food production environments.

    "Rapid and reliable detection of Listeria is critical for effective environmental monitoring programs," said Dr. Jeremy Yarwood, Chief Scientific Officer at Neogen. "AOAC PTM certification of Listeria Right Now provides customers with added confidence that the test delivers dependable performance when and where it matters most, helping them take timely action to protect their facilities, brands, and reputation."

    Neogen offers one of the industry's most comprehensive portfolios of environmental monitoring and pathogen detection solutions, backed by global validation, regulatory acceptance, and decades of scientific expertise. The addition of AOAC PTM certification for Listeria Right Now further strengthens Neogen's position as a trusted partner to food producers around the world. To learn more about the Neogen® Molecular Detection Assay - Listeria Right Now™ visit info.neogen.com/listeriarightnow.

    About Neogen

    Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

    Safe Harbor Statement

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the test's ability to allow food manufacturers to quickly identify potential contamination risks and strengthen environmental monitoring workflows, the test's ability to seamlessly integrate into existing food safety programs and support proactive decision-making across a wide range of food production environments, the future positioning of Neogen's test one of the fastest molecular tests available for Listeria testing, and the addition of AOAC PTM certification for Listeria Right Now strengthening Neogen's position as a trusted partner to food producers around the world.

    These "forward-looking statements" are management's present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated.

    These risks include, but are not limited to risks relating to the integration of the 3M Food Safety business, risks related to potential tax benefits realized through the 3M transaction, risks related to tariffs and other trade measures, risks related to our international operations and expansion into new geographic markets, risks related to identified material weaknesses in our internal control over financial reporting, risks related to promoting internal growth and identifying and integrating acquisitions, risks related to failure of our systems infrastructure and security breaches of our information systems, risks related to disruption in our manufacturing and service operations, risks related to disruption of third-party package delivery services or pricing increases, risks related to dependence on key suppliers, risks related to the use of distributors for product sales, risks related to the development of new products and technologies, risks related to our ability to maintain a positive reputation, risks related to customer loss, risks related to increased raw material costs, risks related to anti-bribery, trade control, trade sanctions, and anti-corruption laws, risks related to changes in domestic and foreign laws and regulations, risks related to tax audits and changes in tax laws in different jurisdictions, risks related to deterioration in profitability, cash flow, and asset impairments, risks related to competition, risks related to agricultural marketplace, risks related to our substantial indebtedness, risks related to the outcomes of litigation and other legal proceedings, risks related to our ability to obtain and protect intellectual property, risks related to patent infringement challenges, risks related to governmental regulation, risks related to our ability to attract and retain key personnel, risks related to product or service liability claims, risks related to changing political conditions, risks related to climate change, risks related to our inability to meet stakeholder expectations around environmental, social, and governance objectives, risks related to tax legislation, and other factors discussed under the heading "Risk Factors" contained in Item 1A of the company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on July 30, 2025, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Neogen is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260423600877/en/

    Media Contact:

    Lauren White

    [email protected]

    Get the next $NEOG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEOG

    DatePrice TargetRatingAnalyst
    7/29/2025Outperform → Mkt Perform
    William Blair
    12/19/2024$15.00Buy
    Guggenheim
    6/16/2023$22.00Overweight
    Wells Fargo
    11/22/2022Mkt Perform → Outperform
    William Blair
    7/12/2022$25.00Neutral
    Piper Sandler
    More analyst ratings

    $NEOG
    SEC Filings

    View All

    Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    4/20/26 6:59:24 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by Neogen Corporation

    10-Q - NEOGEN CORP (0000711377) (Filer)

    4/9/26 4:03:42 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    4/9/26 7:01:47 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neogen's Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced that its Molecular Detection Assay - Listeria Right Now™ rapid environmental monitoring test has received AOAC® Performance Tested Methods℠ (PTM) certification (No. 042604), validating the test's performance for the enrichment-free detection of viable and non-viable Listeria species on stainless steel surfaces. The technology allows technicians to perform the assay without first enriching the sample by growing the bacteria in culture media. Combined with the ease-of-use and speed advantages associated with Neogen's Molecular Detection System ™, this makes Neogen's test one of the fastest molecu

    4/23/26 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Reports Third Quarter Fiscal Year 2026 Financial Results

    Fiscal third quarter 2026 revenue of $211.2 million Food Safety revenue growth of 2.6%, Core Growth1 of 4.0%; Animal Safety revenue growth of (20.1%), Core Growth1 of (8.7%) due primarily to third-party supplier challenges in the quarter Net loss of $17.0 million in the third quarter 2026 with GAAP EPS of $(0.08), Adjusted Net Income of $19.4 million and Adjusted EPS of $0.09 Third quarter 2026 cash flow from operations of $22.7 million and free cash flow of $11.1 million Adjusted EBITDA1 of $48.2 million; Adjusted EBITDA margins1 of 22.8% increases sequentially by 110 basis points Petrifilm® manufacturing transition remains on track for November FY27; Company has initiated

    4/9/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary

    Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive experience in the life sciences industry. She has served more than 10 years as a public company chief legal and compliance officer and board secretary, as well as five years as a public company board member. Over her more than 25-year career, she has led legal, compliance, government relations, corporate communications and human resources functions, operating in complex, fast-moving environments.

    4/8/26 8:00:00 AM ET
    $CNTX
    $NEOG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $NEOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $252 worth of shares (23 units at $10.94) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/17/26 3:12:55 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $486 worth of shares (49 units at $9.93) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/2/26 4:36:07 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $1,279 worth of shares (137 units at $9.33) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    1/16/26 9:04:01 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Stacey Jennifer Evans

    3 - NEOGEN CORP (0000711377) (Issuer)

    4/13/26 8:29:20 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $252 worth of shares (23 units at $10.94) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/17/26 3:12:55 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $486 worth of shares (49 units at $9.93) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/2/26 4:36:07 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neogen downgraded by William Blair

    William Blair downgraded Neogen from Outperform to Mkt Perform

    7/29/25 3:32:27 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Guggenheim initiated coverage on Neogen with a new price target

    Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00

    12/19/24 8:18:19 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Wells Fargo initiated coverage on Neogen with a new price target

    Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00

    6/16/23 7:34:39 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Financials

    Live finance-specific insights

    View All

    Neogen Reports Third Quarter Fiscal Year 2026 Financial Results

    Fiscal third quarter 2026 revenue of $211.2 million Food Safety revenue growth of 2.6%, Core Growth1 of 4.0%; Animal Safety revenue growth of (20.1%), Core Growth1 of (8.7%) due primarily to third-party supplier challenges in the quarter Net loss of $17.0 million in the third quarter 2026 with GAAP EPS of $(0.08), Adjusted Net Income of $19.4 million and Adjusted EPS of $0.09 Third quarter 2026 cash flow from operations of $22.7 million and free cash flow of $11.1 million Adjusted EBITDA1 of $48.2 million; Adjusted EBITDA margins1 of 22.8% increases sequentially by 110 basis points Petrifilm® manufacturing transition remains on track for November FY27; Company has initiated

    4/9/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen to Release Third-Quarter Fiscal Year 2026 Financial Results on April 9, 2026

    Neogen® Corporation (NASDAQ:NEOG) will issue its third-quarter earnings release before the opening of the market on Thursday, April 9, 2026. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time. During the call, Neogen management will provide a financial overview and business update of the company's performance for the third-quarter of fiscal year 2026. The conference call can be accessed by dialing: Toll-Free - North America: (1) 888-660-6264 International: (+1) 646-517-3975 Conference ID: 70064# The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "E

    3/30/26 8:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Second-Quarter 2026 Results

    Revenue of $224.7 million, a decrease of 2.8% YoY; Core growth1 increased 2.9% YoY Net loss of $15.9 million; Adjusted Net Income1 of $22.6 million Adjusted EBITDA1 of $48.7 million; Adjusted EBITDA margin1 increased 470 bps sequentially Company hires key senior commercial leaders Petrifilm manufacturing transition remains on track Raising FY 2026 revenue and Adjusted EBITDA guidance 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the second quarter ended November 30, 2025. "I am exceptionally proud of the Neogen team as we have initiated the first phase of our strategic tr

    1/8/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Leadership Updates

    Live Leadership Updates

    View All

    Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary

    Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive experience in the life sciences industry. She has served more than 10 years as a public company chief legal and compliance officer and board secretary, as well as five years as a public company board member. Over her more than 25-year career, she has led legal, compliance, government relations, corporate communications and human resources functions, operating in complex, fast-moving environments.

    4/8/26 8:00:00 AM ET
    $CNTX
    $NEOG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Neogen® Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Bryan Riggsbee as its new Chief Financial Officer effective November 3, 2025. Riggsbee will oversee Neogen's global finance organization and join the company's Executive Leadership Team, reporting directly to Chief Executive Officer Mike Nassif. To ensure a smooth transition, David Naemura is expected to remain with the Company until the end of the calendar year. Riggsbee brings over 25 years of financial leadership experience across the diagnostics and healthcare industries. He joins Neogen from bioMérieux where he served as Chief Financial Officer of its $2 billion Nort

    10/30/25 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that William Boehm has chosen to retire from the Company's Board of Directors, effective October 23, 2025. Mr. Boehm has served on Neogen's Board since 2011 and currently serves on the Compensation & Talent Management Committee and chairs the Audit Committee. "On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors. "Bill's insight, guidance, and commitment to our mission have been invaluable in shaping Neogen's path forward. His contributions

    8/14/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 4:28:12 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 11:16:20 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    2/13/24 5:09:41 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care